Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice

International Journal of Cancer

Volumn 80, Issue 4, 1999, Pages 595-599

  Tempero, Richard M ^a   Rowse, Gerald J ^b   Gendler, Sandra J ^b   Hollingsworth, Michael A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER TRANSPLANTATION; CELL COMPARTMENTALIZATION; CELL SURVIVAL; CELL TRANSFORMATION; CYTOTOXIC T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; TRANSGENIC MOUSE; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; AUTOIMMUNE DISEASES; CA-15-3 ANTIGEN; FEMALE; HUMANS; IMMUNOGLOBULIN G; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 0033521882     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990209)80:4<595::AID-IJC18>3.0.CO;2-B     Document Type: Article

References (23)

1. AKKARAJU, S., CANAAN, K. and GOODNOW, C.C., Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells. J. exp. Med., 186, 2005-2012 (1997).
2. APOSTOLOPOULOS, V., OSINSKI, C. and MCKENZIE I.F.C., MUC1 cross-reactive Galα(1,3) antibodies in humans switch immune responses from cellular to humoral. Nature (Med.), 4, 315-320 (1998).
3. DISIS, M.L. and CHEEVER, M.A.. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res., 71, 343-371 (1997).
4. GENDLER, S.J. and SPICER, A.P., Epithelial mucin genes. Ann. Rev. Physiol., 57, 607-634 (1995).
5. GOODNOW, C.C., CROSBIE, J., ADELSTEIN, S., LAVOIE, T.B., SMITH-GILL, S.J., BRINK, R.A., PRITCHARD-BRISCOE, H., WOTHERSPOON, J.S., LOBLAY, R.H., RAPHAEL, K., TRENT, R.J. and BASTEN, A., Altered immunoglobulin expression and functional silencing of self-reaclive B lymphocytes in transgenic mice. Nature (Lond.), 334, 676-682 (1988).
6. GOUREVITCH, M. M., MENSDORFF-POUILLY, S.V., LITVINOV, S.V., KENEMANS, P., VAN KAMP, G.J., VERSTRAETEN, A.A. and HILGERS, J., Polymorphic epithelial mucin (MUC1)-containing circulating immune complexes in carcinoma patients. Brit. J. Cancer, 72, 934-938 (1995).
7. GRAHAM, R.A., BURCHELL, J.M. and TAYLOR-PAPADIMITRIOU, J., The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol. Immunother., 42, 71-80 (1996).
8. HARA, I., TAKECHI, Y. and HOUGHTON, A.N., Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. exp. Med., 182, 1609-1614 (1995).
9. HAREUVENI, M., GAUTIER, C., KIENY, M.P., WRESCHNER, D., CHAMBON, P. and LATHE, R., Vaccination against tumor cells expressing breast cancer epithelial tumor antigen. Proc. nat. Acad. Sci. (Wash.), 87, 9498-9502 (1990).
10. HOUGHTON, A.N. and LLOYD, K.O., Stuck in the MUC on the long and winding road. Nature (Med.), 4, 270-271 (1998).
11. IOANNIDES, C.G., FISK, B., JEROME, K.R., IRIMURA, T. WHARTON, J.T. and FINN, O.J., Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol., 151, 3693-3703 (1993).
12. JEROME, K.R., BARND, D.L., BENDT, K.M., BOYER, C.M., TAYLOR-PAPADIMITRIOU, J., MCKENZIE, I.F.C., BAST, R.C., JR. and FINN, O.J., Cytotoxic T-lymphocytes derived from patients with breast adenocarcinomas recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 51, 2908-2916 (1991).
13. KARANIKAS, V. and 12 OTHERS, Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. clin. Invest., 100, 2783-2792 (1997).
14. KOTERA, Y., FONTENOT, J.D., PECHER, G., METZGAR, R.S. and FINN, O.J., Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 54, 2856-2860 (1994).
15. MENSDORFF-POUILLY, S.V., GOUREVITCH, M.M., KENEMANS, P., VERSTRAETEN, A.A., LITVINOV, S.V., VAN KAMP, G.J., MEIJER, S., VERMORKEN, J. and HILGERS, J., Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumors. Europ. J. Cancer. 32A, 1325-1331 (1996).
16. NEMAZEE, D.A. and BURKI, K., Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class 1 antibody genes. Nature (Lond.), 337, 562-566 (1989).
17. OKAMOTO, M., MURAKAMI, M., SHIMIZU, A., OZAKI, S., TSUBATA, T., KUMAGAI, S. and HONJO, T., A transgenic model of autoimmune hemolytic anemia. J. exp. Med., 175, 71-79 (1992).
18. ROWSE, G.J., TEMPERO, R.M., VANLITH, M.L., HOLLINGSWORTH, M.A. and GENDLER, S.J., Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res., 58, 315-321 (1998).
19. RUGHETTI, A., TURCHI, V., GHETTE, C.A., SCAMBIA, G., PANICI, P.B., RONCUCCI, G., MANCUSO, S., FRATI, L. and NUTTI, M., Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res., 53, 2457-2459 (1993).
20. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and absent in MUC1 transgenic mice. J. Immunol. 161, 5500-5506 (1998).
21. XING, P.-X., MICHAEL, M., APOSTOLOPOULOS, V., PRENZOSKA, J., MARSHALL, C., BISHOP, J. and MCKENZIE, I.F.C., Phase I study of synthetic MUC1 peptides in breast cancer. Int. J. Oncol., 6, 1283-1289 (1995).
22. ZHANG, S., GRAEBER, L.A., HELLING, F., RAGUPATHI, G., ADLURI, S., LLOYD, K.O. and LIVINGSTON, P.O., Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res., 56, 3315-3319 (1996).
23. ZOTTER, S., HAGEMAN, P.C., LOSSNITZER, A., MOOI, W.J. and HILGERS, J., Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev., 12, 55-101 (1988).